TY - JOUR
T1 - Erbin is a negative modulator of cardiac hypertrophy
AU - Rachmin, Inbal
AU - Tshori, Sagi
AU - Smith, Yoav
AU - Oppenheim, Amit
AU - Marchetto, Sylvie
AU - Kay, Gillian
AU - Foo, Roger S.Y.
AU - Dagan, Noa
AU - Golomb, Eliahu
AU - Gilon, Dan
AU - Borg, Jean Paul
AU - Razin, Ehud
PY - 2014/4/22
Y1 - 2014/4/22
N2 - ErbB2 interacting protein (Erbin) is a widely expressed protein and participates in inhibition of several intracellular signaling pathways. Its mRNA has been found to be present in relatively high levels in the heart. However, its physiological role in the heart has not been explored. In the present work, we elucidated the role of Erbin in cardiac hypertrophy. Cardiac hypertrophy was induced in mice either by isoproterenol administration or by aortic constriction. The level of Erbin was significantly decreased in both models. Erbin-/- mice rapidly develop decompensated cardiac hypertrophy, and following severe pressure overload all Erbin-/- mice died from heart failure. Down-regulation of Erbin expression was also observed in biopsies derived from human failing hearts. It is known that Erbin inhibits Ras-mediated activation of the extracellular signal-regulated kinase (ERK) by binding to Soc-2 suppressor of clear homolog (Shoc2). Our data clearly show that ERK phosphorylation is enhanced in the heart tissues of Erbin-/- mice. Furthermore, we clearly demonstrate here that Erbin associates with Shoc2 in both whole hearts and in cardiomyocytes, and that in the absence of Erbin, Raf is phosphorylated and binds Shoc2, resulting in ERK phosphorylation. In conclusion, Erbin is an inhibitor of pathological cardiac hypertrophy, and this inhibition ismediated, at least in part, by modulating ERK signaling.
AB - ErbB2 interacting protein (Erbin) is a widely expressed protein and participates in inhibition of several intracellular signaling pathways. Its mRNA has been found to be present in relatively high levels in the heart. However, its physiological role in the heart has not been explored. In the present work, we elucidated the role of Erbin in cardiac hypertrophy. Cardiac hypertrophy was induced in mice either by isoproterenol administration or by aortic constriction. The level of Erbin was significantly decreased in both models. Erbin-/- mice rapidly develop decompensated cardiac hypertrophy, and following severe pressure overload all Erbin-/- mice died from heart failure. Down-regulation of Erbin expression was also observed in biopsies derived from human failing hearts. It is known that Erbin inhibits Ras-mediated activation of the extracellular signal-regulated kinase (ERK) by binding to Soc-2 suppressor of clear homolog (Shoc2). Our data clearly show that ERK phosphorylation is enhanced in the heart tissues of Erbin-/- mice. Furthermore, we clearly demonstrate here that Erbin associates with Shoc2 in both whole hearts and in cardiomyocytes, and that in the absence of Erbin, Raf is phosphorylated and binds Shoc2, resulting in ERK phosphorylation. In conclusion, Erbin is an inhibitor of pathological cardiac hypertrophy, and this inhibition ismediated, at least in part, by modulating ERK signaling.
UR - http://www.scopus.com/inward/record.url?scp=84899079029&partnerID=8YFLogxK
U2 - 10.1073/pnas.1320350111
DO - 10.1073/pnas.1320350111
M3 - Article
C2 - 24711380
AN - SCOPUS:84899079029
SN - 0027-8424
VL - 111
SP - 5902
EP - 5907
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 16
ER -